Statement of Changes in Beneficial Ownership (4)
April 03 2020 - 4:06PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Fenimore Christopher R. |
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC.
[
REGN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) VP Controller |
(Last)
(First)
(Middle)
777 OLD SAW MILL RIVER ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
4/1/2020 |
(Street)
TARRYTOWN, NY 10591
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 4/1/2020 | | M(1) | | 1200 | A | $30.63 | 14297 | D | |
Common Stock | 4/1/2020 | | S(1) | | 63 | D | $478.77 | 14234 | D | |
Common Stock | 4/1/2020 | | S(1) | | 69 | D | $479.0 | 14165 | D | |
Common Stock | 4/1/2020 | | S(1) | | 58 | D | $480.28 | 14107 | D | |
Common Stock | 4/1/2020 | | S(1) | | 62 | D | $482.09 | 14045 | D | |
Common Stock | 4/1/2020 | | S(1) | | 124 | D | $483.58 (2) | 13921 | D | |
Common Stock | 4/1/2020 | | S(1) | | 3 | D | $484.14 | 13918 | D | |
Common Stock | 4/1/2020 | | S(1) | | 137 | D | $488.76 (3) | 13781 | D | |
Common Stock | 4/1/2020 | | S(1) | | 201 | D | $489.48 (4) | 13580 | D | |
Common Stock | 4/1/2020 | | S(1) | | 70 | D | $491.65 | 13510 | D | |
Common Stock | 4/1/2020 | | S(1) | | 134 | D | $492.45 (5) | 13376 | D | |
Common Stock | 4/1/2020 | | S(1) | | 174 | D | $493.24 (6) | 13202 | D | |
Common Stock | 4/1/2020 | | S(1) | | 37 | D | $494.16 | 13165 | D | |
Common Stock | 4/1/2020 | | S(1) | | 68 | D | $497.99 | 13097 | D | |
Common Stock | | | | | | | | 1401 | I | By 401(k) Plan |
Common Stock | | | | | | | | 1897 | I | By Trust (7) |
Common Stock | | | | | | | | 509 | I | by 2017 GRAT |
Common Stock | | | | | | | | 2284 | I | by 2018 GRAT |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Incentive Stock Option (right to buy) | $30.63 | 4/1/2020 | | M (1) | | | 1200 | (8) | 12/14/2020 | Common Stock | 1200 | $0.0 | 2180 | D | |
Explanation of Responses: |
(1) | Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). |
(2) | Represents volume-weighted average price of sales of 124 shares of Company stock on April 1, 2020 at prices ranging from $483.35 to $483.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. |
(3) | Represents volume-weighted average price of sales of 137 shares of Company stock on April 1, 2020 at prices ranging from $488.57 to $488.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. |
(4) | Represents volume-weighted average price of sales of 201 shares of Company stock on April 1, 2020 at prices ranging from $489.17 to $489.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. |
(5) | Represents volume-weighted average price of sales of 134 shares of Company stock on April 1, 2020 at prices ranging from $492.07 to $492.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. |
(6) | Represents volume-weighted average price of sales of 174 shares of Company stock on April 1, 2020 at prices ranging from $493.14 to $493.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. |
(7) | These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust. |
(8) | The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Fenimore Christopher R. 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 |
|
| VP Controller |
|
Signatures
|
/s/**Christopher R. Fenimore | | 4/2/2020 |
**Signature of Reporting Person | Date |
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2023 to Sep 2024